Latest information on COVID-19
Support teaching, research, and patient care.
Dr. Menon is the Rachel L. and Walter F. Nichols, MD, Professor of Psychiatry & Behavioral Sciences and, Professor, by courtesy, of Neurology & Neurological Sciences and Education at Stanford University. Dr. Menon is director of the Stanford Cognitive and Systems Neuroscience Laboratory, which seeks to advance fundamental knowledge of human brain function and dysfunction, and to use this knowledge to help children and adults with psychiatric and neurological disorders. Research in Dr. Menon's lab emphasizes a tight integration of cognitive, behavioral, neuroscience and computational methodologies. Students and researchers in his lab come from a wide range of disciplines, including psychiatry, neurology, psychology, neuroscience, electrical and biomedical engineering, and computer science, to conduct research in a highly interdisciplinary setting. Dr. Menon received his BSc (Honors) in physics from the Indian Institute of Technology and his PhD in computer science from the University of Texas at Austin. He did a postdoctoral fellowship in neurophysiology at the University of California, Berkeley under the direction of Prof. Walter J. Freeman, III. He came to Stanford University as a Sinclair Foundation Research Fellow and joined the faculty in 2000.Over the past two decades, Dr. Menon’s research has led to major breakthroughs in our understanding of the architecture, function, and development of these large-scale distributed human brain networks. Dr. Menon and his team were among the first to discover that the human brain is organized into specialized and interacting networks of brain regions, which has resulted in a paradigm shift in how we investigate human brain function and cognition. Virtually every psychiatric and neurological disorder has been probed with the scientific framework Dr. Menon and his team first developed. This includes discovery of the default mode, frontoparietal, and salience networks, and their functions, which have led to elucidation of how deficits in access, engagement and disengagement of large-scale brain networks play a prominent role in psychopathology, providing novel insights into brain mechanisms underlying cognitive, affective, and social function and dysfunction that cut across multiple neurological and psychiatric disorders. Dr. Menon’s research has been cited over 77,000 times, with an h-index of 115 (Google Scholar). Dr. Menon is a ISI Highly Cited Researcher in Neuroscience (2013, 2014, 2015, 2016, 2017, 2018; ISI, Thompson Reuters), and in 2019 and 2020 he was named an ISI Highly Cited Researcher with Cross-Field impact.
Dr. Menon’s lab uses advanced imaging and computational techniques to investigate the functional and structural architecture of cognitive networks in the human brain. His lab also investigates how disruptions in specific brain circuits impact behavior, cognition, emotion and learning in individuals with neurodevelopmental, psychiatric and neurological disorders. Current projects include: (1) typical and atypical development of large-scale brain networks; (2) disruption of large-scale brain networks in psychopathology; (3) cognitive, affective, and social information processing systems in children with autism; (4) neural basis of learning disabilities in children; (5) brain training and interventions to remediate poor cognitive skills in children with learning disabilities; (6) computational methods for probing dynamic functional circuits; (7) computational modeling of large-scale functional and structural brain networks.
Imaging the Nucleus Accumbens in Major Depressed Patients 'Treated With Pramipexole
We hope to learn how a brain circuit that is important to the understanding of depression,
anhedonia and positive affect responds to a novel pharmaceutical treatment for depression and
related symptoms. Adults who have a diagnosis of major depression and are not completely
responsive to antidepressant medication will be sought out for participation; as will an
equal number of adults not suffering from the disorder. Those suffering from depression will
be given pramipexole, an investigational medication for eight weeks during which information
will be collected about mood, cognition, and brain function. Adults not suffering from
depression will also be evaluated with these measures.
Stanford is currently not accepting patients for this trial.
For more information, please contact Jennifer Keller, PHD, 650-724-0070.
View full details